1802425-99-5
- Product Name：Milvexian
- Molecular Formula：C28H23Cl2F2N9O2
- Purity：99%
- Molecular Weight：626.4
Product Details:
CasNo： 1802425-99-5
Molecular Formula： C28H23Cl2F2N9O2
Buy High Quality High Purity Milvexian 1802425-99-5 with Cheapest Price
- Molecular Formula:C28H23Cl2F2N9O2
- Molecular Weight:626.4
Milvexian(Cas 1802425-99-5) Usage
|
Description |
Milvexian, also known by its synonyms BMS-986177 and JNJ-70033093, is an orally bioavailable, small-molecule inhibitor of factor XIa (FXIa). It is designed to specifically target and inhibit factor XIa, a key component in the blood coagulation cascade. By inhibiting factor XIa, milvexian helps to prevent the formation of blood clots, thereby reducing the risk of thrombosis. |
| Uses |
Milvexian is being studied for various indications related to thrombosis prevention and treatment. As of late 2021, it was under investigation for the prevention of blood clots in patients undergoing surgery. Additionally, Bristol-Myers Squibb studied milvexian for the prevention of stroke from 2018 to 2023. Milvexian has shown robust efficacy in preventing and treating thrombosis, making it a promising candidate for anticoagulant therapy. |
1802425-99-5 Relevant articles
Toward the Development of a Manufacturing Process for Milvexian: Scale-Up Synthesis of the Side Chain
S Wagschal，D Broggini，TDC Cao，P Schleiss，K Paun，J Steiner，AL Merk，J Harsdorf，W Fiedler，S Schirling
, Organic Process Research & Development 2023-04-03
To support the clinical development program of milvexian (BMS-986177/JNJ-70033093), a FXIa inhibitor that recently completed phase II clinical trials, we improved the discovery route to deliver the suitable quantity of key intermediate 1 for clinical supply.
Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis
X Wang，Q Li，F Du，N Shukla，AR Nawrocki，M Chintala
TH Open
Milvexian's antithrombotic efficacy was characterized in a rabbit arteriovenous (AV) shunt model of venous thrombosis and compared with the factor Xa inhibitor apixaban and the direct thrombin inhibitor dabigatran. MethodsThe AV shunt model of thrombosis was conducted in anesthetized rabbits.
Relevant Products
-
Moxifloxacine HclCAS：186826-86-8
-
SparsentanCAS：254740-64-2
-
TinidazoleCAS：19387-91-8
